Clinical Trials
285
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (179 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Intracerebral Hemorrhage(CBSinICH)
- Conditions
- Intracerebral HemorrhageBrain Hemorrhage
- Interventions
- Drug: Calculus bovis sativus (CBS)Drug: Natural Calculus Bovis(NCB)
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT07080632
- Locations
- 🇨🇳
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei 430000, Hubei, China
Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
- Conditions
- Lupus or SLEInterstitial Lung DiseaseSystemic Lupus Erythematosus
- Interventions
- Drug: Immunosuppressant other than CYC
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT07077486
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Observing the Efficacy and Safety of Different Drugs Used in Real-world Familial Mediterranean Fever (FMF) Cases
- Conditions
- Familial Mediterranean Fever (FMF )
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT07077473
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: TUDCA (Tauroursodeoxycholic Acid) SupplementationDrug: Immune checkpoint inhibitor (ICI)
- First Posted Date
- 2025-07-15
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT07064668
- Locations
- 🇨🇳
Tongji Medical college of HUST, Wuhan, Hubei, China
AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)
- Conditions
- Hepatecellular CarcinomaHepatectomy
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 353
- Registration Number
- NCT07062380
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 57
- Next
News
Novel In Vivo CD19 CAR-T Therapy Achieves Complete Remission in Aggressive DLBCL Without Lymphodepletion
A heavily pretreated patient with relapsed/refractory diffuse large B-cell lymphoma achieved complete remission within 28 days following a single dose of Genocury Biotech's novel in vivo CD19 CAR-T therapy.
Sintilimab Plus Bevacizumab Shows Promise in Relapsed Ovarian Clear Cell Carcinoma
A phase II trial (INOVA) found that sintilimab combined with bevacizumab demonstrated activity in patients with relapsed or persistent ovarian clear cell carcinoma.